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Copyright © 2009 AHC Malignant fibrous histiocytoma (MFH) as soft tissue sarcoma would not be especially note-
worthy, but primary hepatic MFH reports are extremely rare. Herein, we report ezrin expres-
sion in tumor tissues from two primary hepatic MFH cases with different prognoses. Cases
1 and 2 were both women, ages 45 and 70 years, respectively. Case 1 had an 11×10 cm
liver tumor in segment (S) 3, and case 2 had two liver tumors, 12×8 cm in S5 and 10×7 cm
in S8. Neither had any other systemic tumors. Cases 1 and 2 survived for two year and ten
months and for eight and a half months, respectively, after the initial tumor resection. Micro-
scopically, the tumors of these two cases were similar and showed proliferation of atypical
cells, including spindle, pleomorphic and multi-nucleated giant cells arranged in storiform,
sheet and/or fascicle patterns, with scattered foci of inflammatory cells, indicating MFH.
Ezrin expression in tumor tissue from case 1 was sparse, whereas that of case 2 showed
strong ezrin expression in many tumor cells. The present results indicate ezrin immuno-
reactivity in primary hepatic MFH to correlate possible with prognosis, which is consistent
with reports on some other types of malignancies.
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I. Introduction
Malignant fibrous histiocytoma (MFH), first reported
by O’Brien and Stout [17] in 1964, was initially considered
to be rare. At a later time, MFH was recognized rather fre-
quently among soft tissue tumors usually occurring in the
extremities of middle-aged or elderly patients. However, the
working group of World Health Organization for classifica-
tion of tumors of soft tissue and bone met in 2002 [23], and
suggested that the term of MFH was synonymous with un-
differentiated pleomorphic sarcoma, which has become a
diagnosis of exclusion accounting for less than 5% of adult
sarcoma. MFH less commonly involves the abdomen and
retroperitoneum, and Weiss and Enzinger [21] reported 16%
of MFH in a review of 200 cases to involve these sites. How-
ever, primary MFH of the liver is extremely rare. A review
of 232 primary hepatic sarcomas, all histologically con-
firmed by the Armed Forces Institute of Pathology, from
1982 to 1990, identified hepatic MFH in only 11 (4.74%)
[9]. MFH of the liver was first reported in 1985 [2, 5], and to
date, only 35 cases have been described in the English liter-
ature, including recent reports by Anagnostopoulos et al. [3],
Ding et al. [6], Ye et al. [24], Chen et al. [4] and Li et al.
[13].
As for prognosis-related markers of malignant neo-
plasms in cytological and/or histological examinations,
Akisawa et al. [1] reported high levels of ezrin expression
by human pancreatic adenocarcinoma cell lines with high
metastatic potential and Khanna et al. [10] suggested ezrin
to possibly be a key factor in the metastasis of osteo-
sarcoma, based on a microarray analysis. Ezrin is an 80 kilo-Sugitani et al. 84
dalton protein and is present in placental microvilli, the
microvillous surface of acid-secreting parietal cells of the
gastric gland [20], membrane ruffles of cultured cells and
growth cones of cultured neurons. The ezrin protein belongs
to the ezrin-radixin-moesin (ERM) cytoskeleton-associated
protein family, which are linkers between membrane pro-
teins and actin filaments. The ezrin has a potentially impor-
tant role in the cortical cytoskeleton, and may participate in
the regulation of several cellular functions. Intensive inves-
tigations have shown strong ezrin immunoreactivity in
tumor tissues to correlate with a poor prognosis in patients
with malignancies, such as astrocytic tumors [8], melanoma
[14], rhabdomyosarcoma [25], osteosarcoma [11], highly
malignant soft tissue sarcoma [22], colorectal cancer [7]
and squamous cell carcinoma of the head and neck [15].
However, positive and negative correlations between ezrin
immunoreactivity and prognosis were found in ovarian
carcinoma [12, 16] and pancreatic adenocarcinoma [1, 19].
Based on these findings, ezrin expression is considered to
promote metastasis and therefore to be a possible prognostic
factor in some types of malignancies.
We experienced two cases with primary MFH of the
liver in our university hospital. MFH of the liver is generally
recognized as having a poor prognosis and both cases ulti-
mately had the same outcome. However, one case died with-
in a year while the other survived for nearly three years after
tumor resection. We investigated ezrin expression using
tumor sections from both cases. Only one report, to our
knowledge, has described ezrin expression as an immuno-
histological prognostic factor in hepatic MFH [13]. This
is because hepatic MFH itself is a rare tumor. Herein, we
describe the possible correlation between clinical outcome
and immunohistochemical expression of ezrin in primary
hepatic MFH.
II. Materials and Methods
Clinical courses of two cases
The clinical course of Case 1, a 45-year-old Japanese
woman, was as follows: She was followed up for a com-
plaint of epigastralgia, at a nearby hospital for 4 months, and
a hepatic mass was detected by computed tomography (CT)
examination. It was located mainly in segment (S) 3. She
was admitted to our hospital. A thorough systemic examina-
tion revealed no tumors anywhere else in the body. The pa-
tient underwent left hepatic resection under a preoperative
diagnosis of possible intrahepatic cystadenocarcinoma. No
tumors were found anywhere in the body, except that in the
liver, intraoperatively. She was discharged from the hospi-
tal. However, hepatic recurrence was found in the remaining
liver and partial resection of the right lobe was performed
two years and five months later from the first operation. The
absence of tumors anywhere in the body, other than the liver,
was confirmed. Four months later from the second opera-
tion, surgery was again required. During the operation, a
recurrent tumor invading the duodenum and pancreas was
identified and gastro-jejunostomy was performed without
tumor resection. Her final admission was due to abdominal
fullness caused by an enlarged tumor and she died approxi-
mately two years and ten months after the initial resection.
Autopsy revealed a recurrent MFH tumor that was located in
the omental bursa and cause of death was considered to be
due to sepsis.
The clinical course of Case 2, a 70-year-old Japanese
woman, was as follows: She had undergone hysterectomy
due to uterine prolapse at the age of 64 years. She was
followed up under a diagnosis of possible pancreatitis at a
neighborhood hospital one year prior to the admission de-
scribed herein. Icterus and a liver tumor were recognized,
and chemotherapy was administered at a local hospital in her
hometown. She was referred for surgical treatment and was
admitted to our hospital. On admission, two tumors were
found in the right hepatic lobe on CT. A thorough systemic
examination revealed no tumors anywhere else in the body.
The liver tumors showed multi-cystic dilation of intrahepatic
bile ducts, within the solid tumor masses. The patient under-
went hepatic resection of S4, S5 and S8 under a preoperative
diagnosis of intrahepatic bile duct cystadenocarcinoma.
Postoperative recovery was uneventful and she was dis-
charged from the hospital. However, recurrence in the liver
and multiple lung metastases developed and she died ap-
proximately eight and a half months after the resection, at
another hospital. Autopsy was not performed.
In both cases, anti-hepatitis C virus antibody and
hepatitis B virus surface antigen were negative on sero-
logical examinations, levels of alpha-fetoprotein (AFP),
carcinoembryonic antigen (CEA) and carbohydrate antigen
19-9 in serum were within normal limits, and preoperative
needle biopsy examinations were not performed.
Thus, though their final outcomes were the same, the
courses after tumor resection differed markedly between
cases 1 and 2. Informed consent was obtained from both
cases.
Histopathology and immunohistochemistry
Histopathological and immunohistochemical examina-
tions were performed on formalin-fixed and paraffin-
embedded tissue sections of the resected tumors. Immuno-
histochemical staining was performed to detect expressions
of vimentin, alpha-1-antitrypsin, alpha-1-antichymotrypsin,
CD68, S-100 protein, desmin, alpha-smooth muscle actin,
myoglobin, myogenin, CD45 (leukocyte common antigen),
CD30, Ki-67, epithelial membrane antigen, cytokeratin,
AFP, CEA and ezrin. All antibodies used for pathological
diagnosis except ezrin were from DakoCytomation
(Glostrup, Denmark). Immunohistochemistry, except that
for ezrin, employed the DAKO Autostainer according to the
manufacturer’s instructions. Monoclonal anti-ezrin antibody
(clone 3C12) was obtained from Sigma-Aldrich (St. Louis,
MO, USA). A positive control for ezrin immunostaining was
used in the sections of placental microvilli. Based on a pre-
investigation, sections from cases 1 and 2 were pretreated at
100°C with EDTA buffer at pH 8.5 for 1 hr and were incu-
bated with 1:4000 diluted anti-ezrin antibody at 37°C for 1Hepatic MFH with Ezrin Immunoreactivity 85
hr with an auto-immunostaining device (Ventana NX Sys-
tem, Ventana Medical Systems Inc, Tucson, AZ, USA), and
all steps were carried out according to the manufacturer’s
instructions. Sections were observed microscopically
(Olympus Corporation, Tokyo, Japan). The intensity and
distribution of ezrin expression were estimated for both
cases.
III. Results
Macroscopic findings of the liver in our two cases were
as follows. The tumor from case 1 (Fig. 1) had a clear border
measuring 11×10 cm on the cut surface. The tumor was
mostly solid, milky-white in color and partially cystic with
necrosis and hemorrhage. The tumors from case 2 (Fig. 2)
both had clear borders, with one measuring 12×8 cm, in
proximity to S5, and the other 10×7 cm, in proximity to S8.
The cut surface showed both tumors to be yellowish-white
in color. Necrosis was seen in both the S5 and the S8 tumor,
and hemorrhage in the S8 tumor. The two tumors from case
2 were close but clearly not connected to each other.
Histopathological findings of the liver tumors from
cases 1 (Fig. 3A and 3B) and 2 (Fig. 3C and 3D) were
basically quite similar, and the two tumors from case 2 had
nearly the same histopathological features. Microscopically,
routine hematoxylin and eosin (H&E) sections from the
tumors showed proliferation of atypical cells composed
of spindle, pleomorphic and multi-nucleated giant cells
arranged in storiform, sheet and/or fascicle patterns contain-
ing areas of hemorrhage, coagulation necrosis and fibrosis.
In both cases, nuclear atypia was equally prominent and
mitoses were common (approximately 3–5 in 10 fields of
high power view). Scattered foci of inflammatory cellular
infiltration were also recognized. In comparison with the
tumor from case 1, those from case 2 had slightly higher
cellularity and more frequent multi-nucleated giant cells.
No osteoid, atypical adipocytes, rhabdoid cells or epithelial
patterns were evident. The tumors showed infiltrative
growth, but neither capsule nor fibrous septa formation
within the tumor mass. The non-neoplastic areas had an
essentially normal appearance, with no evidence of either
chronic hepatitis or liver cirrhosis. Immunohistochemical
examinations revealed the tumor cells to be positive for
vimentin, alpha-1-antitrypsin, alpha-1-antichymotrypsin and
CD68. The ratios of cells positive for Ki-67 to tumor cells
were approximately 15% and 25% in cases 1 and 2, respec-
tively. There were no differences in staining patterns or
stain affinities for these antibodies. Epithelial membrane
antigen, cytokeratin, S-100 protein, desmin, alpha-smooth
muscle actin, myoglobin, myogenin, CD45, CD30, AFP and
CEA were all negative. The final pathological diagnosis of
MFH was made for both cases.
Interestingly, the immunohistochemical detection of
ezrin expression showed cytoplasmic or membranous stain-
ing but it differed markedly between cases 1 and 2. In case 1,
the immunoreactivity against ezrin in tumor cells was weak
and showed a scattered distribution (Fig. 4A). In contrast, in
case 2 the staining was more intense and was diffusely ob-
served in pleomorphic, mononuclear and/or multi-nucleated
giant tumor cells (Fig. 4B and 4C). The ratios of cells
positive for ezrin to tumor cells were less than 10% and
approximately 40% in cases 1 and 2, respectively.
IV. Discussion
Two significant features are required to make a diagno-
sis of primary MFH of the liver. One involves the histo-
pathology of the liver tumor. The morphological features
of the tumor in our present cases were within the spectrum
of soft tissue MFH, as described above. The other is that
the clinicopathologic criteria for a primary hepatic origin
must be met. Li et al. [13] proposed their criteria for pri-
mary hepatic MFH in a review of seven cases, as follows:
solitary or multifocal liver neoplasm without evidence
Fig. 1. Macroscopic findings of the cut surface of the tumor in case 1.
Fig. 2. Macroscopic tumor findings of the tumor in case 2. A; A
large and a small tumor are present in the liver. Cut surfaces of the
tumors are also shown (B and C). The tumors were located mainly
in segments 8 and 5, respectively.Sugitani et al. 86
Fig. 3. Microscopic features of the MFH tumors in cases 1 (A, B) and 2 (C, D). They are quite similar. The storiform-pleomorphic patterns seen
in MFH cases 1 and 2 are shown in A and C, respectively. Proliferation of spindle, bizarre, pleomorphic and multi-nucleated giant cells in MFH
cases 1 and 2 are shown in B and D, respectively. In comparison with case 1, the tumor from case 2 had slightly higher cellularity and more fre-
quent multi-nucleated giant cells. (H&E staining, original magnification A, ×100; B, ×400; C and D, ×200).
Fig. 4. Ezrin expressions in tumor cells from case 1 (A) and case 2
(B and C). C is high power view of B. Immunostaining with hema-
toxylin counter-staining is shown; original magnification of A and B
is ×400, and that of C is ×1000.Hepatic MFH with Ezrin Immunoreactivity 87
of a preexisting, concurrent, or subsequently discovered
primary lesion in any part of the body. The most important
point, in concluding that the origin is hepatic, is to exclude
metastasis and direct invasion of MFH arising in other
sites. In our cases, no tumors were found in any other
organs or sites on radio-imaging examinations or intra-
operative gross examination at the initial operation. These
two cases showed features compatible with the criteria for
primary MFH of the liver. In most hepatic MFH cases
described in the literature [13], the tumor showed positive
immunostaining for vimentin (8/9 cases), alpha-1-antitryp-
sin (6/7), alpha-1-antichymotrypsin (7/7) and CD68 (2/2),
while being negative for cytokeratin (10/10), S-100 protein
(9/9) and desmin (9/9). Our cases had the same immuno-
histochemical findings, allowing exclusion of myogenic
and lipoblastic malignancies and sarcomatoid carcinoma.
The immunohistochemical findings of the present cases
were thus consistent with MFH.
The prognosis of a patient with soft tissue MFH de-
pends greatly on tumor size, location and the adequacy of
the initial surgical excision [18]. Tumor size is considered to
be a clinically significant prognostic factor in hepatic MFH.
On the other hand, histopathological grade is thought to ac-
tually be closely related to prognosis. In a previous study,
when ezrin and other ERM family proteins were activated,
they interacted with membrane proteins and the actin cyto-
skeleton, and as a result, they affected such processes as
migration, adhesion, invasion and survival of the cell. These
processes are important for the establishment and progres-
sion of malignant neoplasm. Therefore, the ezrin expression
could be considered in relation with prognosis in several
types of malignancies, including MFH. In the present study,
the immunohistochemical expressions of ezrin clearly dif-
fered between cases 1 and 2. Clinically, they showed mark-
edly different survival durations from the initial tumor resec-
tion. Recently, Li et al. [13] reported that three patients with
high ezrin immunoreactivity died of their tumors within one
year while two others with low ezrin immunoreactivity sur-
vived for more than four years after surgery. Their results
indicated tumors with high immunohistochemical ezrin ex-
pression to be associated with a poor prognosis, whereas low
expression was associated with a rather good prognosis.
Although primary hepatic MFH is extremely rare, we could
confirm the relationship between ezrin expression and prog-
nosis, obtaining results similar to those reported by Li et al.
In conclusion, we have presented herein the immuno-
histochemical expression patterns of ezrin in two primary
hepatic MFH cases. In determining the prognosis of patients
with primary hepatic MFH, as this disease is extremely rare,
use of the histological grade of H&E stained sections only is
a limitation. Immunohistochemical ezrin staining was found
to be useful as a supplementary method for determining
prognosis. This study verified the immunohistochemical
results reported by Li et al. [13], which showed a possible
correlation between immunohistochemical ezrin expression
and the outcomes of patients with primary hepatic MFH.
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